medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2025, Number 3

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2025; 23 (3)

Cancer and skin: the hidden connection of cutaneous metastases

López SK, Santamaría DDG, Lacy NRM

Language: Spanish
References: 24
Page: 233-240
PDF size: 326.69 Kb.


ABSTRACT

Introduction: cutaneous metastases are secondary manifestations of internal malignancies, frequently signaling an undiagnosed or recurrent primary tumor. Although uncommon, their incidence is rising.
Development: these metastases typically arise from tumor cell dissemination through hematogenous, lymphatic, or contiguous pathways. They commonly present as painless, erythematous nodules located near the primary tumor site. Diagnosis hinges on clinical evaluation, dermoscopy, and histopathological studies.
Discussion: the identification of cutaneous metastases is crucial, as they are often the initial sign of an underlying cancer. Early detection facilitates appropriate oncologic management. Despite this, the prognosis generally remains poor, with an average survival of 7.5 months post-diagnosis.
Conclusion: despite their rarity, cutaneous metastases serve as a vital clinical alert. Dermatologists play a critical role in their early detection, thereby potentially improving patient prognosis through timely diagnosis and intervention.


REFERENCES

  1. Vernemmen AIP, Li X, Roemen GMJM, Speel EM, Kubat B, HausenAZ et al., Cutaneous metastases of internal malignancies: asingle-institution experience, Histopathology 2022; 81(3):329-41.

  2. Queirós CS, Filipe PL y Soares de Almeida L, Cutaneous metastasesfrom solid neoplasms in the 21st century: a retrospectivestudy from a Portuguese tertiary care center, J Eur Acad DermatolVenereol 2020; 34(6):1218-24.

  3. Souza BCE, Miyashiro D, Pincelli MS y Sanches JA, Cutaneousmetastases from solid neoplasms. Literature review, An Bras Dermatol2023; 98(5):571-9.

  4. Otsuka I, Cutaneous metastasis after surgery, injury, lymphadenopathy,and peritonitis: possible mechanisms, Int J Mol Sci 2019;20(13):3286.

  5. Fernández-Antón Martínez MC, Parra-Blanco V, Avilés IzquierdoJA y Suárez Fernández RM, Metástasis cutáneas de origen visceral,Actas Dermosifiliogr 2013; 104(10):841-53.

  6. Joosse SA y Pantel K, Genetic traits for hematogeneous tumorcell dissemination in cancer patients, Cancer Metastasis Rev 2016;35(1):41-8.

  7. Erol B, Ufuk U, Husamettin T, Yasin U, Aslihan C y Koray K, Truehematogenous metastases of melanoma on contralateral skingraft donor site: a case report, Melanoma Res 2008; 18(6):443-6.

  8. Karaman S y Detmar M, Mechanisms of lymphatic metastasis,J Clin Invest 2014; 124(3):922-8.

  9. Moy AP, Duncan LM y Kraft S, Lymphatic invasion and angiotropismin primary cutaneous melanoma, Lab Invest 2017; 97(2):118-29.

  10. Yun SJ, Park HY, Lee JS, Park MH, Lee JB y Won YH, Clinicopathologicalcorrelation of cutaneous metastatic breast carcinomausing lymphatic and vascular markers: lymphatics aremainly involved in cutaneous metastasis, Clin Exp Dermatol 2012;37(7):744-8.

  11. Habermehl G y Ko J, Cutaneous metastases: a review and diagnosticapproach to tumors of unknown origin, Arch Pathol Lab Med2019; 143(8):943-57.

  12. Jaros J, Hunt S, Mose E, Lai O y Tsoukas M, Cutaneous metastases:a great imitator, Clin Dermatol 2020; 38(2):216-22.

  13. Alonso-de-León T, Cano-Aguilar LE, Hernández-Ramírez HH yVega-Memije ME, Metástasis cutáneas diagnosticadas en unhospital de segundo nivel desde 1985 al 2020, Med Cutan IberoLat Am 2023; 51(3).

  14. Villani A, Scalvenzi M, Micali G, Lacarrubba F, Fornaro L, MartoraF et al., Management of advanced invasive melanoma: newstrategies, Adv Ther 2023; 40(8):3381-94.

  15. Swetter SM, Tsao H, Bichakjian CK, Curiel-Lewandrowski C,Elder DE, Gershenwald JE et al., Guidelines of care for the managementof primary cutaneous melanoma, J Am Acad Dermatol2019; 80(1):208-50.

  16. Swetter SM, Thompson JA, Albertini MR, Barker CA, BaumgartnerJ, Boland G et al., nccn guidelines insights: melanoma, cutaneous,version 2.2021, J Natl Compr Canc Netw 2021; 19(4):364-76.

  17. Kamin´ska-Winciorek G, Pils´niak A, Piskorski W y Wydman´ski J,Skin metastases in the clinical and dermoscopic aspects, SeminOncol 2022; 49(2):160-69.

  18. Scott-Emuakpor R, Reza-Soltani S, Altaf S, Nr K, Kołodziej F, Sil-Zavaleta S et al., Mammary Paget’s disease mimicking benignand malignant dermatological conditions: clinical challenges anddiagnostic considerations, Cureus 2024; 16(7):e65378.

  19. Kapatia G, Sahu S, Rohilla M, Gupta P, Gupta N, Srinivasan Ret al., Clinical and morphological spectrum of cutaneous metastaseson cytology: a study of 225 cases, Cytopathology 2021;32(2):233-7.

  20. Hussein MR, Skin metastasis: a pathologist’s perspective, J CutanPathol 2010; 37(9):e1-20.

  21. Méndez-Flores S, Gatica-Torres M, Zamora-González A y Domínguez-Cherit J, Metástasis cutáneas, Med Int Méx 2015; 31:434-40.

  22. Gan EY, Chio MT y Tan WP, A retrospective review of cutaneousmetastases at the National Skin Centre Singapore, Australas JDermatol 2015; 56(1):1-6.

  23. Weide B, Faller C, Büttner P, Pflugfelder A, Leiter U, Eigentler TKet al., Prognostic factors of melanoma patients with satellite orin-transit metastasis at the time of stage iii diagnosis, plos One2013; 8(4):e63137.

  24. Song X, Zhao Z, Barber B, Farr AM, Ivanov B y Novich M, Overallsurvival in patients with metastatic melanoma, Curr Med Res Opin2015; 31(5):987-91.




2020     |     www.medigraphic.com